Search

Your search keyword '"Laura Braun-Parvez"' showing total 19 results
Start Over Author "Laura Braun-Parvez"
19 results on '"Laura Braun-Parvez"'

1. Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report

Author

Thibault Bahougne, Jérome Olagne, Marion Munch, Laura Braun-Parvez, Marie-Pierrette Chenard, Véronique Frémeaux-Bacchi, Sophie Caillard, Philippe Baltzinger, Michel Greget, Laurence Kessler, and Bruno Moulin

Subjects
Atypical hemolytic and uremic syndrome, Complement C3, Islets of Langerhans transplantation, Case report, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Abstract Background We here report on the first observation of a C3 mutation that is related to atypical hemolytic and uremic syndrome (aHUS), which occurred in a pancreatic islet transplant patient. Immunosuppressive treatments, such as calcineurin inhibitors, have been linked to undesirable effects like nephrotoxicity. Case presentation A 40-year-old man with brittle diabetes, who was included in the TRIMECO trial, became insulin-independent 2 months after pancreatic islet transplantation. About 15 months after islet transplantation, the patient exhibited acute kidney injury due to aHUS. Despite plasma exchange and eculizumab treatment, the patient developed end-stage renal disease. A genetic workup identified a missense variant (p.R592Q) in the C3 gene. In vitro, this C3 variant had defective Factor I proteolytic activity with membrane proteins as cofactor proteins, which was thus classified as pathogenic. About 1 year after the aHUS episode, kidney transplantation was carried out under the protection of the specific anti-C5 monoclonal antibody eculizumab. The patient had normal kidney function, with preserved pancreatic islet function 4 years later. Conclusions Pancreatic islet transplantation could have triggered this aHUS episode, but this link needs to be clarified. Although prophylactic eculizumab maintains kidney allograft function, its efficacy still needs to be studied in larger populations.

Published
2020
Full Text
View/download PDF

2. Tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients

Author

Ilies Benotmane, Jérôme Olagne, Gabriela Gautier Vargas, Noëlle Cognard, Francoise Heibel, Laura Braun-Parvez, Nicolas Keller, Jonas Martzloff, Peggy Perrin, Romain Pszczolinski, Bruno Moulin, Samira Fafi-Kremer, and Sophie Caillard

Abstract

ObjectiveThis single-center retrospective study evaluated the use of tixagevimab-cilgavimab as an early treatment for COVID-19 in kidney transplant recipients (KTRs) during the omicron wave.MethodsKTRs were deemed at high risk for moderate-to-severe COVID-19 in presence of at least one comorbidity (age >60 years, diabetes, obesity, or cardiovascular disease) associated with a weak humoral response (ResultsOf the 61 KTRs at high risk, 26 received tixagevimab-cilgavimab. COVID-19-related hospitalizations (3.8% versus 34%, p=0.006) and oxygen need (3.8% versus 23%, p=0.04) were significantly less frequent in patients who received tixagevimab-cilgavimab. In addition, non-significant trends towards a lower number of ICU admissions (3.8% versus 14.3% p=0.17) and deaths (0 versus 3, p=0.13) were observed after administration of tixagevimab-cilgavimab. Ten of the 73 low-risk KTRs received tixagevimab-cilgavimab, and no significant clinical benefit was observed in this subgroup.ConclusionEarly administration of tixagevimab-cilgavimab may be clinically useful in high-risk KTRs with COVID-19; however, no major benefit was observed for low-risk patients.

Published
2022

3. A rapid decline in the anti-receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab-cilgavimab administration

Author

Ilies Benotmane, Aurélie Velay, Gabriela-Gautier Vargas, Jérôme Olagne, Noëlle Cognard, Françoise Heibel, Laura Braun-Parvez, Jonas Martzloff, Peggy Perrin, Romain Pszczolinski, Bruno Moulin, Samira Fafi-Kremer, and Sophie Caillard

Subjects
Nephrology, SARS-CoV-2, Immunoglobulin G, Spike Glycoprotein, Coronavirus, Humans, COVID-19, Kidney Transplantation
Published
2022

4. Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients

Author

Ilies Benotmane, Aurélie Velay, Gabriela Gautier-Vargas, Jérôme Olagne, Augustin Obrecht, Noëlle Cognard, Françoise Heibel, Laura Braun-Parvez, Nicolas Keller, Jonas Martzloff, Peggy Perrin, Romain Pszczolinski, Bruno Moulin, Samira Fafi-Kremer, Olivier Thaunat, and Sophie Caillard

Subjects
Transplantation, SARS-CoV-2, Immunology and Allergy, Humans, COVID-19, Pharmacology (medical), Sciences du Vivant [q-bio]/Médecine humaine et pathologie, Antibodies, Viral, Kidney Transplantation, Antibodies, Neutralizing
Abstract

The cilgavimab-tixagevimab combination retains a partial in vitro neutralizing activity against the current SARS-CoV-2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we examined whether preexposure prophylaxis with cilgavimab-tixagevimab can effectively protect kidney transplant recipients (KTRs) against the omicron variant. Of the 416 KTRs who received intramuscular prophylactic injections of 150 mg tixagevimab and 150 mg cilgavimab, 39 (9.4%) developed COVID-19. With the exception of one case, all patients were symptomatic. Hospitalization and admission to an intensive care unit were required for 14 (35.9%) and three patients (7.7%), respectively. Two KTRs died of COVID-19-related acute respiratory distress syndrome. SARS-CoV-2 sequencing was carried out in 15 cases (BA.1, n = 5; BA.1.1, n = 9; BA.2, n = 1). Viral neutralizing activity of the serum against the BA.1 variant was negative in the 12 tested patients, suggesting that this prophylactic strategy does not provide sufficient protection against this variant of concern. In summary, preexposure prophylaxis with cilgavimab-tixagevimab at the dose of 150 mg of each antibody does not adequately protect KTRs against omicron. Further clarification of the optimal dosing can assist in our understanding of how best to harness its protective potential.

Published
2022

5. Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study

Author

Ilies Benotmane, Gabriela Gautier-Vargas, Noëlle Cognard, Jérôme Olagne, Françoise Heibel, Laura Braun-Parvez, Jonas Martzloff, Peggy Perrin, Romain Pszczolinski, Bruno Moulin, Samira Fafi-Kremer, and Sophie Caillard

Subjects
kidney transplant recipients, COVID-19, anti-SARS-CoV-2 mRNA vaccine, serological response, prediction, Medicine (miscellaneous)
Abstract

Kidney transplant recipients (KTRs) displays marked inter-individual variations in magnitude of immune responses to anti-SARS-CoV-2 vaccination. The aim of this large single-center study was to identify the predictive factors for serological response to the mRNA-1273 vaccine in KTRs. We also devised a score to optimize prediction with the goal of implementing a personalized vaccination strategy. The study population consisted of 564 KTRs who received at least two doses of the mRNA-1273 vaccine. Anti-RBD IgG titers were quantified one month after each vaccine dose and until six months thereafter. A third dose vaccine was given when the antibody titer after the second dose was

Published
2022

6. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine

Author

Ilies Benotmane, Gabriela Gautier-Vargas, Samira Fafi-Kremer, Noëlle Cognard, Jérôme Olagne, Laura Braun-Parvez, Jonas Martzloff, Peggy Perrin, Francoise Heibel, Bruno Moulin, and Sophie Caillard

Subjects
Immunity, Cellular, Vaccines, Messenger RNA, business.industry, medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.disease, Kidney Transplantation, Kidney transplant, Vaccination, Immunization, Nephrology, Immunity, Antibody Formation, Immunology, medicine, RNA, Messenger, Renal replacement therapy, business, Letter to the Editor, Kidney transplantation
Published
2021

7. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19

Author

Aurélie Velay, Noëlle Cognard, Gabriela Gautier-Vargas, Pierre Gantner, Peggy Perrin, Floriane Gallais, Ilies Benotmane, Sophie Caillard, Francoise Heibel, Samira Fafi-Kremer, Jonas Martzloff, Laura Braun-Parvez, Jérôme Olagne, Bruno Moulin, univOAK, Archive ouverte, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Strasbourg, LabEx Transplantex [Strasbourg], Université de Strasbourg (UNISTRA), and Fédération de Médecine Translationnelle de Strasbourg (FMTS)

Subjects
2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Kidney transplant, Letter to the Editors, Immunology and Allergy, Medicine, Humans, Pharmacology (medical), RNA, Messenger, Letter to the Editor, Transplantation, Messenger RNA, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, business.industry, SARS-CoV-2, COVID-19, Kidney Transplantation, Transplant Recipients, Past history, Antibody response, Immunization, Immunology, Antibody Formation, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

A recent study demonstrated that a single dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-based vaccine is sufficient to mount a robust immunological response in immunocompetent subjects with a previous history of coronavirus disease 2019 (COVID-19).1,2 While research has suggested that immunocompromised kidney transplant recipients (KTRs) who received mRNA-based vaccines show low immunization rates,3-5 the question as to whether this also applies to KTRs with a past history of COVID-19 remains unanswered. The aim of this study was to describe the results of immunization after one dose of the mRNA-1273 SARS-CoV-2 vaccine in KTRs who were already seropositive at baseline because of previous exposure to SARS-CoV-2.

Published
2021

8. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Author

Ilies Benotmane, Samira Fafi-Kremer, Laura Braun-Parvez, Bruno Moulin, Peggy Perrin, Jérôme Olagne, Francoise Heibel, Gabriela Gautier-Vargas, Noëlle Cognard, Jonas Martzloff, and Sophie Caillard

Subjects
0301 basic medicine, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.medical_treatment, Population, 030232 urology & nephrology, Kidney transplant, Serology, 03 medical and health sciences, 0302 clinical medicine, medicine, Renal replacement therapy, Seroconversion, education, Kidney transplantation, Messenger RNA, education.field_of_study, business.industry, Immunosuppression, medicine.disease, Virology, Vaccination, 030104 developmental biology, Antibody response, Nephrology, business
Abstract

Data concerning the anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in kidney transplant recipients (KTRs) are currently lacking. Here, we sought to examine this issue by analyzing the serological response observed in 241 KTRs after a first vaccine injection. Our results indicate that KTRs have a weak anti-SARS-CoV-2 antibody response, ultimately resulting in a low seroconversion rate (26/241, 10.8%). This phenomenon likely stems from a high immunosuppression burden in this clinical population.

Published
2021

9. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

Author

Cécile Couchoud, Florian Bayer, Carole Ayav, Clémence Béchade, Philippe Brunet, François Chantrel, Luc Frimat, Roula Galland, Maryvonne Hourmant, Emmanuelle Laurain, Thierry Lobbedez, Lucile Mercadal, Olivier Moranne, Abdelhamid Abbassi, Alain Debure, Abdallah Guerraoui, Abdelatif Benmoussa, Abdelaziz Hamani, Abdelaziz Ziane, Abdelhamid Nefti, Abdelkader Hadj, Abderrahim El Amari, Abderrahmane Ghazali, Abo Bakr Abd El Fatah Mohamed, Achour Laradi, Adel Ben Ahmed, Adel Sahar, Adele Pillet, Adeline Lacraz, Adnan Moinat, Afshin Massoumi, Agathe Pardon, Agnes Caillette Beaudoin, Agnes Chapelet Debout, Agnes Mariot, Ahmed Rachi, Aida Afiani, Aime Remy Boula, Al Jalaby, Alain Cremault, Alain Fournier, Alain Jeanson, Alain Lyon, Alain Nony, Alain Robert, Alain Slingeneyer, Alanor Agnes Labatide, Albane Brodin Sartorius, Albert Bensman, Albert Fournier, Alex Ranlin, Alex Vido Sandor, Alexandra Colombo, Alexandra Duhem, Alexandra Stancu, Alexandre Dufay, Alexandre Dumoulin, Alexandre Ebel, Alexandre Klein, Alexandre Martin, Alexandre Mouneimne, Alexandre Seidowsky, Alfio De Martin, Alfredo Zannier, Ali Aizel, Ali Hafi, Ali Zineddine Diddaoui, Alim Heyani, Alina Mocanu, Alina Preda, Aline Hafi, Aline Talaszka, Alyette Duquesne, Amar Amaouche, Amel Ghemmour, Amelie Simon, Amina Skalli, Amine Boukadida, Amr Ekhlas Ragab Eid, Ana Fedorca, Anabelle Baillet, Anais Poyet, Ancuta Bouffandeau Giorgita, Anderson Ratsimbazafy, Andre Pruna, Angel Argiles, Angelo Testa, Ann Karolien Vandooren, Anne Jolivot, Anne Kolko Labadens, Anne Lataste, Anne Maisin, Anne Paris, Anne Sechet, Anne Wuillai, Anne Elisabeth Heng, Anne Gaelle Josse, Anne Helene Querard, Anne Helene Reboux, Anne Laure Adra, Anne Laure Faller, Anne Laure Leclerc, Anne Laure Poitou, Annie Lahoche Manucci, Antoine Jacquet, Antoine Pommereau, Antoine Thierry, Arezki Adem, Arielle Chapelet, Arnaud Del Bello, Arnaud Delezire, Arnaud Garnier, Arnaud Guerard, Arnaud Klisnick, Arnaud Lionet, Arnaud Roccabianca, Arnaud Stolz, Arthur Capdeville, Asma Allal, Assem Alrifai, Assetou Diarrassouba, Assia Djema, Assia Ferhat Carre, Astrid Godron Dubrasquet, Atman Haddj Elmrabet, Audrey Jegado, Aurelia Bertholet Thomas, Aurelie Davourie Salandre, Aurelie Pajot, Aurelien Lorthioir, Aurelien Tiple, Aurore Sury, Ayman Abokasem, Ayman Sarraj, Bachir Henaoui, Baher Chaghouri, Bassem Wehbe, Beatrice Ball, Beatrice Viron, Belkassem Issad, Benedicte Hodemon Corne, Benedicte Janbon, Benjamin Deroure, Benjamin Savenkoff, Benoit Jonon, Benoit Vendrely, Benyakoub Djelaleddine, Bernard Ohry, Bernard Painchart, Bernard Strullu, Bernard Temperville, Bertin Ebikili, Bertrand Hacq, Bertrand Morel, Bilal Aoun, Blanca Muniz, Bouchra Chlih, Brahim Amara, Brice Mayor, Brigitte Gilson, Brigitte Llanas, Brigitte Zins, Bruno Bourgeon, Bruno Coevoet, Bruno Guery, Bruno Legallicier, Bruno Paris, Bruno Ranchin, Bruno Seigneuric, Camelia Ghiciuc Dita, Camelia Prelipcean, Carine Achard Hottelart, Carine Diet, Carlos Frangie, Carlos Vela, Carmina Muresan, Carole Deprele, Caroline Araujo, Caroline Bidault, Caroline Creput, Caroline Delclaux, Caroline Du Halgouet, Caroline Favennec, Caroline Freguin, Caroline Gourraud Vercel, Caroline Mesguen, Caroline Ndomo Obama, Caroline Poitou, Caroline Preissig Dirhold, Caroline Roubiou, Catherine Albert, Catherine Bessin, Catherine De Marion Gaja, Catherine Godart, Catherine Lasseur, Catherine Leocardi, Catherine Lumbroso, Catherine Melander, Catherine Michel, Catherine Quere Maurouard, Catherine Rouannet, Catherine Taddei, Cathy Verove, Cecile Guiraud, Cecile Tafelin, Cecile Turc Baron, Cedric Formet, Cedric Pinier, Celia Lessore De Ste Foy, Celine Granolleras, Chaouki Bennini, Charles Cartou, Charles Chazot, Charlotte Jouzel, Cherif Badid, Christa Roubicek, Christel Viaud, Christelle Verrier, Christian Chuet, Christian Combe, Christian Dabot, Christian Duvic, Christian Emond, Christian Lagarde, Christian Lamotte, Christian Pain, Christiane Mousson, Christie Lorriaux, Christine Beauchamp, Christine Fumeron, Christine Le Gurun, Christine Leroy, Christine Pietrement, Christine Richer, Christophe Bouaka, Christophe Charasse, Christophe Goupy, Christophe Ridel, Cindy Castrale, Cindy Detourne, Clair Francois, Claire Presne, Claire Trivin, Clarissa Von Kotze, Claude Bernard, Claude Bonniol, Claude Desvergnes, Claude Raharivelina, Claudia Nistor, Claudine Gueret, Claudine Lloret, Claudine Saltiel, Clelia Rosati, Clementine Rabate, Corina Stanescu, Corinne Ferrandini, Corinne Guibergia, Corinne Lemoine, Corinne Passeron, Cynthia Kahil, Cyril Garrouste, Cyril Vo Van, Cyrille Jolimoy, Dalila Kesraoui, Damien Jolly, Damien Thibaudin, Dan Teboulle, Daniel Daubresse, Daniel Louvet, Daniel Rasamimanantsoa, Daniel Toledano, Daniela Babici, Daniela David, Daniela Dincu, Danielle Bruno, Delia May, Delphine Haussaire, Delphine Henriet Viprey, Denis Bugnon, Denis Fouque, Denis Morin, Derradji Nour, Diab Mohamed Mahmoud, Diana Istrati Cristescu, Didier Aguilera, Didier Coste, Didier Hamel, Didier Le Chapois, Didier Testou, Dilaver Erbilgin, Djamal Dahmane, Doan Bui Quang, Dominique Bertrand, Dominique Besnier, Dominique Blanchier, Dominique Briffa, Dominique Caux, Dominique Durand, Dominique Fleury, Dominique Guerrot, Dominique Hestin, Dominique Jaubert, Dominique Joly, Dominique Lombart, Dominique Pagniez, Dominique Pierre, Dominique Schohn, Donatien Ikonga, Dorina Visanica, Dorothee Bazin, Edouard Boury, Edouard Maksour, Ekoue Agbonon, Elarbi Harrami, Elena Marcu, Elena Tudorache, Elisabeth Caniot, Elisabeth Semjen, Elisabeth Tomkiewicz, Elise Scheidt, Elke Gaboriau, Elodie Lamouroux, Elsa Guiard, Elsa Martin Passos, Emerson Nsembani, Emilie Fache, Emilie Kalbacher, Emilie Pambrun, Emilie Pincon, Emma Allain Launay, Emmanuel Baron, Emmanuel Dupuis, Emmanuel Villar, Emmanuelle Charlin, Emmanuelle Hecquet, Emmanuelle Kohler, Emmanuelle Rosier, Enrique Figueroa, Eric Azoulay, Eric Canivet, Eric Daugas, Eric Gauthier, Eric Laruelle, Eric Le Guen, Eric Legrand, Eric Moumas, Eric Postec, Eric Prinz, Eric Renaudineau, Estelle Desport, Estelle Ricard Sutra, Etienne Berard, Etienne Ged, Etienne Robin, Eve Vilaine, Evelyne Bargas, Evelyne Mac Namara, François Combarnous, Fatima Yazbeck, Fabien Gerard, Fabien Metivier, Fabien Parazols, Fabien Soulis, Fabrice Garnier, Fadhila Pech Messaoudene, Fadi Haidar, Fanny Boullenger, Fanny Lepeytre, Fanny Leroy, Fares Frejate, Farid Bellahsene, Farid Bellhasene, Farid Saidani, Fatouma Toure, Faycal Kriaa, Fazia Nemmar, Fernando Vetromile, Florence Chalmin, Florence Lucats, Florence Sens, Florence Villemain, Florent Plasse, Fouad Lebhour, Francis Schillinger, Franck Berge, Franck Bourdon, Franck Bridoux, Franck Reynaud, Francois Babinet, Francois Basse, Francois Chantrel, Francois Clair, Francois Coulomb, Francois De Cornelissen, Francois Glowacki, Francois Marchal, Francois Maurice, Francois Nobili, Francois Pourreau, Francois Provot, Francois Roux Amani, Francoise Broux, Francoise Bulte, Francoise Heibel, Francoise Leonetti, Francoise Moussion Schott, Frank Le Roy, Frederic Besson, Frederic Lavainne, Frederic Tollis, Frederique Bocquentin, Frederique Meeus, Frederique Vecina, Friederike Von Ey, Gabriel Balit, Gabriel Choukroun, Gabriel Gruget, Gabriel Huchard, Gabriella Golea, Gabrielle Duneau, Gaelle Lefrancois, Gaelle Pelle, Gaetan Lebrun, Genevieve Dumont, Georges Brillet, Georges Deschenes, Georges Mourad, Georges Stamatakis, Geraldine Cazajous, Geraldine D'ythurbide, Geraldine Robitaille Wiart, Gerard Cardon, Gerard Champion, Gerard Deschodt, Gerard Mangenot, Gerard Motte, Gerard Schortgen, Ghada Boulahia, Ghassan Maakaroun, Ghylene Bourdat Michel, Gilbert Zanetta, Gilles Hufnagel, Gilles Messier, Giorgina Piccoli, Gregoire Couvrat Desvergnes, Guillaume Bobrie, Guillaume Bonnard, Guillaume Clement, Guillaume Jean, Guillaume Queffeulou, Guillaume Seret, Guillaume Vernin, Guy Delavaud, Guy Lambrey, Guy Rostoker, Gwenaelle Poussard, Gwenaelle Roussey Kesler, H. Leon, Habib Aboubekr, Hacene Boulechfar, Hacene Sekhri, Hadia Hebibi, Hadjira Benalia, Hafed Fessi, Hafsabhai Atchia, Haiat Bittar, Hakim Maiza, Hakim Mazouz, Hamid El Ali, Hammouche Bougrida, Hans Van Der Pijl, Hassan Lokmane, Hassane Izzedine, Hassen Adda, Helene De Preneuf, Helene Leray, Helene Philippot, Henri Boulanger, Henri Merault, Henri Renaud, Herve Bonarek, Herve Maheut, Hilaire Nzeyimana, Hocine Mehama, Hocine Zaidi, Hugo Weclawiak, Hugues Flodrops, Huseyin Karaaslan, Ibrahim Haskour, Ihssen Belhadj, Imad Almoubarak, Imad Haddad, Ines Castellano, Ines Ferrandiz, Ioana Daniliuc, Ioana Darie, Ioana Enache, Ionut Prunescu, Irenee Djiconkpode, Irina Shahapuni, Isabelle Bouchoule, Isabelle Devriendt, Isabelle Kazes, Isabelle Kolb, Isabelle Landru, Isabelle Poli, Isabelle Rey, Isabelle Segalen, Isabelle Selcer, Isabelle Vernier, Isabelle Vrillon, Ismahane Guenifi, J. Dominique Gheerbrandt, Jacky Potier, Jacques Becart, Jacques Cledes, Jacques Ducros, Jacques Duvic, Jacques Fourcade, Jacques Gaultier, Jacques Jurine, Jacques Lebleu, Jacques Ollier, Jacques Ibsen Charles, Jamal Yazji, Janette Mansour, Jean Arnautou, Jean Brocard, Jean Carolfi, Jean Montoriol, Jean Baptiste Gouin, Jean Bernard Palcoux, Jean Christophe Bendini, Jean Claude Aldigier, Jean Claude Alphonse, Jean Daniel Delbet, Jean Francois Bonne, Jean Francois Cantin, Jean Francois De Fremont, Jean Francois Dessassis, Jean Francois Subra, Jean Francois Valentin, Jean Francois Verdier, Jean Jacques Dion, Jean Jacques Haultier, Jean Jacques Montseny, Jean Louis Bacri, Jean Louis Bouchet, Jean Luc Mahe, Jean Marc Chalopin, Jean Marc Gabriel, Jean Marc Hurot, Jean Marc Lanau, Jean Marie Batho, Jean Marie Coulibaly, Jean Michel Hardin, Jean Michel Marc, Jean Michel Poux, Jean Michel Rebibou, Jean Michel Tivollier, Jean Noel Ottavioli, Jean Paul Faucon, Jean Paul Imiela, Jean Paul Jaulin, Jean Paul Masselot, Jean Paul Ortiz, Jean Philippe Bourdenx, Jean Philippe Devaux, Jean Philippe Hammelin, Jean Pierre Rivory, Jean Pierre Wauquier, Jean Rene Larue, Jean Rene Mondain, Jean Sebastien Borde, Jean Simon Virot, Jean Yves Bosc, Jedjiga Achiche, Jennifer Parasote, Jeremie Diolez, Jerome Harambat, Jerome Potier, Jerome Sampol, Jihad Mustel, Jean Jacques Lefevre, Jocelyne Maurizi, Joel Gamberoni, Joelle Claudeon, Joelle Terzic, Joffrey Rogol, Johnny Sayegh, Jorge Cardozo, Jose Brasseur, Jose Guiserix, Joseph Barsumau, Julie Albaret, Julie Beaume, Julie Sohier Attias, Julien Dehay, Julien Hogan, Julien Journet, Julien Ott, Juliette Baleynaud, Justine Bacchetta, Justine Faucher, Kamel Yousfi, Karim Dardim, Karine Clabault, Karine Moreau, Kedna Thomas, Khaled Sirajedine, Khalil Chedid, Khalil El Kaeoui, Khalil El Karoui, Khedidja Bouachi, Kheira Hue, Khuzama El Nasser, Kodso Akposso, Kristian Kunz, Krzysztof Bijak, Lilia Kihal, L. Rasoloarijaona, Laid Harbouche, Larbi Bencheikh, Larbie Lamriben, Latifa Hanafi, Laura Braun Parvez, Laure Champion, Laure Croze, Laure Eprinchard, Laure Patrier, Laurence Nicolet, Laurence Vrigneaud, Laurent Duflot, Leandre Mackaya, Leila Chenine, Leon Odry, Lili Taghipour Tamiji, Lilia Antri Bouzar, Liliane Ngango Nga Messi, Lionel Le Mouellic, Lise Mandart, Lise Weis, Lise Marie Pouteau, Lora Georgieva, Lorita Vitanova, Lotfi Chalabi, Luc Delvallez, Luc Fromentin, Luc Marty, Luc Monjot, Luciana Spataru, Lucie Bessenay, Lucie Boissinot, Lucie Wajsbrot, Lucien Rakoff, Ludivine Lebourg, Lydie Perez, Lyliane Lafage, Lynda Azzouz, Madeleine Dumoulin, Messaoud Ouziala, Maan Joseph, Mabrouk Brahimi, Maeva Wong Fat, Magalie Fort, Magued Nakhla, Mahdi Abtahi, Mahen Albadawy, Mahmoud Alouach, Mahmoud Mezghani, Maite Daroux, Maklouf Boukelmoune, Malek Dhib, Malik Touam, Malina Dubau, Mamadou Balde, Man Nguyen Khoa, Manfred Ismer, Manolie Mehdi, Manon Laforet, Marc Bouiller, Marc Eugene, Marc Fila, Marc Hazzan, Marc Kribs, Marc Ladriere, Marc Lebot, Marc Padilla, Marc Souid, Marcel Marraoui, Maren Burbach, Maria Manescu, Maria Eugenia Noguera Gonzalez, Mariana Revenco, Marianne Terrasse, Marie Essi, Marie Alice Macher, Marie Beatrice Nogier, Marie Cecile Cazin, Marie Christine Schweitzer Camoin, Marie Christine Thouret, Marie Claude Hannaert, Marie France Servel, Marie Helene Chabannier, Marie Jeanne Coudert Krier, Marie Noelle Catoliquot, Marie Paule Guillodo, Marie Sophie Gavard, Marie Xaviere Vairon Codaccioni, Marina Rabec, Marine Freist, Marion Gauthier, Marion Lemaire, Marion Mehrenberger, Marion Venot, Marios Pongas, Marlene Beaubrun Diant, Martial Levannier, Martine Bertaux, Mathieu Jablonski, Mathieu Sacquepee, Mathilde Dargelos, Mathilde Lemoine, Mathilde Tamain, Matthieu Monge, Matthieu Reberolle, Maud Cousin, Maud Francois, Maurice Baron, Maxime Hoffmann, Maxime Ingwiller, Maxime Touzot, Mederick Mohajer, Mehadji Maaz, Melanie Hanoy, Melanie Marroc, Melodie Cuny, Menno Van Der Straaten, Mf. Serveaux, Michel Basteri, Michel Fen Chong, Michel Hecht, Michel Massad, Michel Normand, Michel Olmer, Michel Tolani, Michel Tsimaratos, Michele Hemery, Michele Kessler, Miguel Esposito, Milad Shenouda, Mimi Kareche, Mina Khalili, Mirella Diaconita, Mohamad Khair Rifard, Mohamed Aladib, Mohamed Belmouaz, Mohamed Brahim, Mohamed Diouani, Mohamed Fodil Cherif, Mohamed Jamali, Mohamed Maghlaoua, Mohamed Meddeb, Mohamed Ramdane, Mohamed Rifaat, Mohamed Sharifull Islam, Mohamed Adnan Abbade, Mokhtar Amrandi, Mokhtar Chawki, Monica Ciobotaru, Monica Indrieis, Monique Chanas, Monique Hoarau, Monzer Tomeh, Moufida Bellou, Mouloud Bouzernidj, Mounia Ammor, Mounir Guergour, Mountassir Benzakour, Mourad Hachicha, Moussa Coulibaly, Mustafa Smati, Mustapha Al Morabiti, Mustapha Amirou, Myriam Isnard, Myriam Pastural, Myriam Pujo, Nourredine Boumendjel, Nabil Majbri, Nabila Goumri, Nadege Mingat, Nader Bassilios, Nadia Kerkeni, Nadia Sedrati, Nadia Soltani, Nadine Maroun, Nadine Neyrat, Nahn Luang, Najeh El Esper, Naji Ammar, Nasredine Ghali, Nasser Hamdini, Natacha Noel, Natacha Potelune, Nathalie Maisonneuve, Nathalie Pertuiset, Nathalie Raynal, Nathalie Vittoz, Nazim Terki, Nelly Castin, Nestor Nankeu, Nicolas Bouvier, Nicolas Keller, Nicolas Legros, Nicolas Peters, Nicolas Quirin, Nicole Lefrancois, Nicole Monnier, Nicole Rance, Niels Bruckmann, Noel Mertens, Nolwenn Lorcy, Olivia Gilbert, Olivier Coldefy, Olivier Drouineau, Olivier Dunand, Olivier Fritz, Olivier Imhoff, Olivier Kourilsky, Olivier Lavelle, Olivier Papin, Olivier Roques, Ophelie Le Maner, Oussamah Fikri Benbrahim, Pablo Antonio Erina Torres, Pablo Antonio Urena Torres, Paolo Malvezzi, Pascal Bindi, Pascal Cluzel, Pascal Fontanier, Pascal Wheatley, Pascale Depraetre, Pascale Dubosq, Pascale Halin, Pascale Sebahoun, Pascale Siohan, Pascale Testevuide, Patrice Deteix, Patrice Nolen, Patricia Hue, Patricia Lemarchand, Patrick Donnadieu, Patrick Fievet, Patrick Fohrer, Patrick Francais, Patrick Giraud, Patrick Hallonet, Patrick Henri, Patrick Michaut, Patrick Niaudet, Patrick Pauly, Patrick Thomas, Patrik Deleaval, Paul Finielz, Paul Stroumza, Paule Hardy Yverneau, Pauline Caillard, Pedro Palacin, Perrine Aubertin, Philippe Attias, Philippe Chauveau, Philippe Coindre, Philippe Coste, Philippe Dubot, Philippe Fournier, Philippe Hiernaux, Philippe Jousset, Philippe Lan Yue Wah, Philippe Lang, Philippe Le Cacheux, Philippe Martin Dupont, Philippe Michel, Philippe Mirgaine, Philippe Moriniere, Philippe Nicoud, Philippe Rieu, Philippe Rousseau, Philippe Sporer, Philippe Thorel, Philippe Vanhille, Philippe Vigeral, Philippe Zaoui, Pierre Bataille, Pierre Brignon, Pierre Filipozzi, Pierre Housset, Pierre Peyronnet, Pierre Ramperez, Pierre Vautrin, Pierre Alexandre Michel, Pierre Francois Westeel, Pierre Louis Carron, Pierre Yves Durand, Pierrot Parent, Piotr Seniuta, François Kuentz, Rabah Fraoui, Rachel Tetaz, Rachid Amaria, Rachid Bourouma, Rachid Djeffal, Rachida Nebbad, Radia Allal, Radu Dimulescu, Rafaat Boustani, Rafik Mesbah, Raifat Makdassi, Raji Diab, Raluca Puslenghea, Raoul Roura, Rateb Khayat, Raymond Azar, Raymond Frayssinet, Regine Monkam, Rehouni Boulahrouz, Remi Boudet, Renato Demontis, Renaud Gansey, Rene Cuvelier, Renee Schmitt, Reschad Noordally, Reynald Binaut, Rezkallah Latif, Richard Dufresne, Richard Montagnac, Richard Reade, Robert Genin, Robert Novo, Rocsana Fickl, Roger Dufresne, Roger Magnol, Roland Issautier, Romain Mortelette, Ronan Delaval, Ronan Lohro, Roseline M'barga, S. Beau, Clémentine Dupuis, Marie Jacques Vidil, Sabria Hacini, Said Dahmoune, Saliha Lekhal, Salima Ahriz Sakso, Salima Saksi, Salvatore Citarda, Samir Boubenider, Samuel Kassis, Sandra Verhille, Sandrine Genestier, Sandrine Muller, Saoussen Krid, Sarah Richter, Sebastien Delbes, Sebastien Mailliez, Sebastien Veillon, Sébastien Nony, Seddick Benarbia, Severine Beaudreuil, Sidi Ali Benyaghla, Simon Duquennoy, Simona Baluta, Simona Boncila, Sonia Mzoughi, Sonia Ribal, Sophie Acamer, Sophie Chauvet, Sophie Girerd, Sophie Ozenne, Sophie Parahy, Sophie Rubens Duval, Sophie Taque, Soraya Menouer, Soumaya Chargui, Stanislas Bataille, Stephane Barbier, Stephane Billion, Stephane Roueff, Stephane Torner, Stephane Jean Martin, Stephanie Coupel, Sylvie Cloarec, Sylvie Lavaud, Sylvie Leou, T. Chatelet, Tania Onesta, Tassadit Benhabib, Tayeb Bensalem, Theodora Dimulescu, Theophile Sawadogo, Thibault Dolley Hitze, Thierry Baranger, Thierry Boudemaghe, Thierry Hannedouche, Thierry Krummel, Thierry Milcent, Thomas Dervaux, Thomas Guincestre, Thomas Kofman, Thomas Raphael, Thomas Sadreux, Tim Ulinski, Tiphaine Guyon Roger, Tomas Serrato, Tomek Kofman, Tony Wong, Toufik Boubia, Ubald Assogba Gbindoun, Usama Khuzaie, Valerie Caudwell, Valerie Chatelet, Valerie Crougneau, Valerie De Precigout, Valerie Drouillat, Valerie Galantine, Valerie Granveau Hugot, Valerie Leroy, Veronique Boubia, Veronique Falque, Veronique Fournier, Veronique Queron, Veronique Viviani, Victor Gueuttin, Victor Panescu, Victorio Menoyo Calonge, Viet Nguyen, Vincent Allot, Vincent Delattre, Vincent Leduc, Vincent Pradier, Violaine Emal Aglae, Viorica Badulescu, Virginia Molina, Virginie Besson, Virginie Chaigne, Waddah Jaber, Wael Boudi, Wael El Haggan, Wen Qin Guillon, Wided Tabbi Aneni, William Hanf, Wladimir Kohn, Xavier Bellenfant, Xavier Moreau Gaudry, Yahsou Delmas, Yannick Knefati, Yannick Saingra, Yannick Tirolien, Youssef Mann, Yvan Brunak, Yves Dimitrov, Yves Doussy, Yves Tanter, Zaid Benabid, Zaara Soltani, Zacharia Boukerroucha, Zafer Takla, Zana Ramanantsialonina, Zara Dickson, Zead Tubail, Zoe Koochaki Pour, Zohra Boukhalfa, Zohra Jacquot, Agence de la biomédecine [Saint-Denis la Plaine], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Caen Normandie (UNICAEN), Normandie Université (NU), CALYDIAL Vienne, Partenaires INRAE, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Armand Trousseau [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Service d'Epidémiologie et Evaluations Cliniques [CHRU Nancy] (Pôle S2R), Centre Universitaire des Maladies Rénales [CHU Caen] (CUMR Caen), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génomique Fonctionnelle (IGF), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Assistance Publique - Hôpitaux de Marseille (APHM), Service de diabétologie [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Service de Diabétologie [CHU Pitié-Salpétrière], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
0301 basic medicine, Male, medicine.medical_treatment, [SDV]Life Sciences [q-bio], 030232 urology & nephrology, Hemodialysis, Home, Disease, MESH: COVID-19 / therapy, registry, Ambulatory Care Facilities, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Aged, 80 and over, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Risk Factors, 80 and over, Prevalence, covid, dialysis, epidemiology, mortality, Aged, Aged, 80 and over, COVID-19, Case-Control Studies, Critical Care, Female, France, Humans, Incidence, Middle Aged, Patient Acuity, Protective Factors, Registries, Renal Dialysis, SARS-CoV-2, Sex Factors, Hypoalbuminemia, MESH: France / epidemiology, education.field_of_study, Incidence (epidemiology), 3. Good health, MESH: COVID-19 / epidemiology, Nephrology, Hemodialysis, medicine.medical_specialty, Population, Lower risk, Article, 03 medical and health sciences, MESH: Sex Factors, Internal medicine, medicine, MESH: SARS-CoV-2, MESH: Renal Dialysis / statistics & numerical data, education, Dialysis, Vascular disease, business.industry, medicine.disease, Former Smoker, MESH: Critical Care / statistics & numerical data, 030104 developmental biology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Home, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, MESH: Hemodialysis, Home / statistics & numerical data
Abstract

The aim of this study was to estimate the incidence of COVID-19 disease in the French national population of dialysis patients, their course of illness and to identify the risk factors associated with mortality. Our study included all patients on dialysis recorded in the French REIN Registry in April 2020. Clinical characteristics at last follow-up and the evolution of COVID-19 illness severity over time were recorded for diagnosed cases (either suspicious clinical symptoms, characteristic signs on the chest scan or a positive reverse transcription polymerase chain reaction) for SARS-CoV-2. A total of 1,621 infected patients were reported on the REIN registry from March 16th, 2020 to May 4th, 2020. Of these, 344 died. The prevalence of COVID-19 patients varied from less than 1% to 10% between regions. The probability of being a case was higher in males, patients with diabetes, those in need of assistance for transfer or treated at a self-care unit. Dialysis at home was associated with a lower probability of being infected as was being a smoker, a former smoker, having an active malignancy, or peripheral vascular disease. Mortality in diagnosed cases (21%) was associated with the same causes as in the general population. Higher age, hypoalbuminemia and the presence of an ischemic heart disease were statistically independently associated with a higher risk of death. Being treated at a selfcare unit was associated with a lower risk. Thus, our study showed a relatively low frequency of COVID-19 among dialysis patients contrary to what might have been assumed., Graphical abstract

Published
2020

10. Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report

Author

Marie-Pierrette Chenard, Philippe Baltzinger, Laura Braun-Parvez, M. Greget, Sophie Caillard, Jérôme Olagne, Bruno Moulin, Véronique Frémeaux-Bacchi, Thibault Bahougne, Marion Munch, Laurence Kessler, Les Hôpitaux Universitaires de Strasbourg (HUS), Institut des Neurosciences Cellulaires et Intégratives (INCI), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Nouvel Hôpital Civil de Strasbourg, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), Nanomédecine Régénérative (NanoRegMed), and Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Male, Nephrology, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Mutation, Missense, 030232 urology & nephrology, 030230 surgery, lcsh:RC870-923, Gastroenterology, Islets of Langerhans, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Case report, medicine, Humans, Pancreatic islet function, Kidney transplantation, Atypical Hemolytic Uremic Syndrome, geography, geography.geographical_feature_category, business.industry, Acute kidney injury, Complement C3, Acute Kidney Injury, Eculizumab, lcsh:Diseases of the genitourinary system. Urology, medicine.disease, Islet, Kidney Transplantation, 3. Good health, Transplantation, Diabetes Mellitus, Type 1, Atypical hemolytic and uremic syndrome, Kidney Failure, Chronic, Islets of Langerhans transplantation, Pancreatic islet transplantation, business, medicine.drug
Abstract

Background We here report on the first observation of a C3 mutation that is related to atypical hemolytic and uremic syndrome (aHUS), which occurred in a pancreatic islet transplant patient. Immunosuppressive treatments, such as calcineurin inhibitors, have been linked to undesirable effects like nephrotoxicity. Case presentation A 40-year-old man with brittle diabetes, who was included in the TRIMECO trial, became insulin-independent 2 months after pancreatic islet transplantation. About 15 months after islet transplantation, the patient exhibited acute kidney injury due to aHUS. Despite plasma exchange and eculizumab treatment, the patient developed end-stage renal disease. A genetic workup identified a missense variant (p.R592Q) in the C3 gene. In vitro, this C3 variant had defective Factor I proteolytic activity with membrane proteins as cofactor proteins, which was thus classified as pathogenic. About 1 year after the aHUS episode, kidney transplantation was carried out under the protection of the specific anti-C5 monoclonal antibody eculizumab. The patient had normal kidney function, with preserved pancreatic islet function 4 years later. Conclusions Pancreatic islet transplantation could have triggered this aHUS episode, but this link needs to be clarified. Although prophylactic eculizumab maintains kidney allograft function, its efficacy still needs to be studied in larger populations.

Published
2020

11. In‐depth virological assessment of kidney transplant recipients with COVID‐19

Author

Aurélie Velay, Clement Baldacini, Noëlle Cognard, Ilies Benotmane, Louise Gontard, Margaux Della-Chiesa, Samira Fafi-Kremer, Dogan Firat Bozman, Floriane Gallais, Marie Josée Wendling, Heloise Delagreverie, Dimitri Bedo, Sophie Caillard, Gabriela Gautier-Vargas, Bruno Moulin, Francoise Heibel, Laura Braun-Parvez, Morgane Solis, Mylene Sagnard, Jérôme Olagne, David Marx, Xavier Bassand, Baptiste Panaget, and Peggy Perrin

Subjects
Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viruses, Enzyme-Linked Immunosorbent Assay, Comorbidity, 030230 surgery, Brief Communication, Antibodies, Viral, Gastroenterology, Kidney transplant, Serology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Nasopharynx, medicine, Immunology and Allergy, Humans, Pharmacology (medical), Viral shedding, Pandemics, Aged, Transplantation, biology, business.industry, SARS-CoV-2, COVID-19, Middle Aged, Viral Load, Kidney Transplantation, Survival Rate, medicine.anatomical_structure, biology.protein, Female, France, Antibody, business, Viral load, Respiratory tract
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread widely, causing coronavirus disease 2019 (COVID-19) and significant mortality. However, data on viral loads and antibody kinetics in immunocompromised populations are lacking. We aimed to determine nasopharyngeal and plasma viral loads via reverse transcription-polymerase chain reaction and SARS-CoV-2 serology via enzyme-linked immunosorbent assay and study their association with severe forms of COVID-19 and death in kidney transplant recipients. In this study, we examined hospitalized kidney transplant recipients with nonsevere (n = 21) and severe (n = 19) COVID-19. SARS-CoV-2 nasopharyngeal and plasma viral load and serological response were evaluated based on outcomes and disease severity. Ten recipients (25%) displayed persistent viral shedding 30 days after symptom onset. The SARS-CoV-2 viral load of the upper respiratory tract was not associated with severe COVID-19, whereas the plasma viral load was associated with COVID-19 severity (P = .010) and mortality (P = .010). All patients harbored antibodies during the second week after symptom onset that persisted for 2 months. We conclude that plasma viral load is associated with COVID-19 morbidity and mortality, whereas nasopharyngeal viral load is not. SARS-CoV-2 shedding is prolonged in kidney transplant recipients and the humoral response to SARS-CoV-2 does not show significant impairment in this series of transplant recipients.

Published
2020

12. Conversion des abords vasculaires d’urgence pour hémodialyse en fistules natives au Rwanda : à propos de 37 cas

Author

Innocent Uyisabye, Jean-de-Dieu Nzambaza, Joseph Ntarindwa, Richard Rwandenzi, Françoise Mantz, Sarah Richter, Jérôme Muhizi, Martine Kibuka, Laura Braun-Parvez, Théogène Twagirumugabe, and Isabelle Kolb

Subjects
Nephrology
Abstract

Resume La prise en charge de patients en hemodialyse chronique au Rwanda est recente. L’acces vasculaire utilise est le plus souvent un catheter. Patients et methodes Trente-sept patients hemodialyses chroniques sur catheter ont ete recrutes sur une periode de 3 ans afin de convertir leur abord vasculaire en fistule native. La selection des patients et le choix du type de fistule ont ete faits lors d’une consultation pluridisciplinaire. Resultats Trente et un patients ont beneficie de la creation de fistule arterio-veineuse (FAV). Le sex-ratio etait de 1,5 et la principale cause de l’insuffisance renale etait l’hypertension arterielle (HTA). Toutes les interventions ont ete realisees sous anesthesie locale ou locoregionale. Par ailleurs, 60 % des FAV creees etaient radio-cephaliques, 35,4 % humero-cephaliques, avec une permeabilite primaire de 77,4 %. Enfin, 64 % des interventions ont ete realisees en ambulatoire. Conclusion Ce travail prouve la faisabilite d’un programme de creation de fistules au Rwanda, permettant ainsi d’eviter les diverses complications qui surviennent avec l’utilisation prolongee d’un catheter. Cette experience a ete rendue possible par la mise en commun des ressources de 4 hopitaux de reference au Rwanda.

Published
2014

13. Gestational Choriocarcinoma Transmission Following Multiorgan Donation

Author

F. Golfier, Philippe Wolf, J.-P. Bergerat, Sophie Caillard, E. Charlin, H. Flicoteaux, B. Moulin, Didier Ducloux, Laura Braun-Parvez, and F. Rolle

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Pancreas transplantation, Liver transplantation, Chorionic Gonadotropin, Gastroenterology, Gestational choriocarcinoma, Metastasis, Pregnancy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Immunology and Allergy, Pharmacology (medical), Choriocarcinoma, Kidney transplantation, Immunosuppression Therapy, Transplantation, Chemotherapy, business.industry, Remission Induction, Middle Aged, medicine.disease, Kidney Transplantation, Tissue Donors, Liver Transplantation, Surgery, Uterine Neoplasms, Female, Pancreas Transplantation, business
Abstract

An accidental transmission of placental choriocarcinoma (CC) from a multiorgan donor to four recipients is reported. The donor was a 26-year-old pregnant woman, died from a cerebral hemorrhage. Histological examination demonstrated the presence of a placental CC. Diagnosis of CC transmission was established on the basis of an increase of human chorionic gonadotrophin hormone (hCG) level. The recipient of combined pancreas-kidney is still in complete remission 2 years after the beginning of chemotherapy without removal of the grafted organs which show optimal function. The recipient of a single kidney was rapidly transplantectomized and treated with actinomycin. At 2 years, she remains in remission. Liver recipient showed intestinal metastasis and died from digestive hemorrhage after an initial response to chemotherapy. Heart recipient had an initial remission under EMA-CO, but at the last report, he showed diffuse metastasis. Published reports on CC transmission are rare. The long-lasting remission of our pancreas-kidney recipient and her good outcome after 2 years make our observation original. Moreover, the high rate of transmission demonstrates the high malignant potential of CC in immunosuppressed patients. Chemotherapy combined or not with transplantectomy in case of nonvital organ, should be discussed.

Published
2010

14. [Emergency vascular access conversion to native arterio veinous fistula: a prospective study of 37 hemodialysis patients in Rwanda]

Author

Isabelle, Kolb, Théogène, Twagirumugabe, Innocent, Uyisabye, Jérôme, Muhizi, Laura, Braun-Parvez, Sarah, Richter, Joseph, Ntarindwa, Jean-de-Dieu, Nzambaza, Richard, Rwandenzi, Martine, Kibuka, and Françoise, Mantz

Subjects
Adult, Male, Patient Selection, Rwanda, Comorbidity, Middle Aged, Arteriovenous Shunt, Surgical, Treatment Outcome, Renal Dialysis, Catheter-Related Infections, Ambulatory Care, Arm, Humans, Kidney Failure, Chronic, Female, Prospective Studies, Emergencies, Peritoneal Dialysis, Vascular Access Devices, Anesthesia, Local
Abstract

Chronic hemodialysis in Rwanda is relatively recent and most of patients are treated with catheters.Thirty-seven patients who require chronic hemodialysis with catheters were evaluated during a 3-years period in order to facilitate the creation of a permanent vascular access for hemodialysis (AVF). Patient selection were made during a multi-disciplinary consultation. The sex-ratio was 1.5 and the main cause of the nephropathy was arterial hypertension.Thirty-one patients benefited from the creation of an arterioveinous fistula. All of the interventions were performed using local or loco-regional anesthesia. Sixty percent of these AVF were radio-cephalic, 35.4% were humero-cephalic. Sixty-four percent of the operations were performed on ambulatory patients, with a primary function for 90% of them.This work proves the feasibility of the creation of AVF in Rwanda, thus allowing to preclude the various complications that arise with the prolonged use of a catheter. This experience was made possible by the pooling of the resources of 4 of Rwanda's leading hospitals. In an early future, the development of vascular surgery will assure the permanence of this care.

Published
2014

15. Risk factors for BK virus infection in the era of therapeutic drug monitoring

Author

Claire Borni-Duval, Bruno Moulin, Sophie Caillard, Francoise Heibel, Laura Braun-Parvez, Peggy Perrin, and Jérôme Olagne

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Biopsy, Viremia, medicine.disease_cause, Gastroenterology, Mycophenolic acid, Tacrolimus, Nephropathy, Young Adult, Risk Factors, Internal medicine, medicine, BK Virus Infection, Humans, Renal Insufficiency, Risk factor, Aged, Transplantation, Polyomavirus Infections, business.industry, virus diseases, Immunosuppression, Middle Aged, Mycophenolic Acid, medicine.disease, Virology, Kidney Transplantation, BK virus, Area Under Curve, BK Virus, Female, Steroids, Drug Monitoring, business, Immunosuppressive Agents, medicine.drug
Abstract

BACKGROUND Overimmunosuppression is a widely recognized risk factor for BK virus (BKV) infection, particularly with the combination of tacrolimus, mycophenolate mofetil (MMF), and steroids. Nevertheless, the exact impact of exposure to tacrolimus and MMF is not well understood. METHODS We examined 240 kidney recipients between 2006 and 2008. BKV was monitored every 2 months in the urine or blood. A kidney biopsy was performed when viremia exceeded 10 copies/mL. RESULTS Ninety-five (40%) patients had sustained viruria, 48 (20%) sustained viremia, and 17 (7%) biopsy-proven polyomavirus-associated nephropathy. The mean time-to-occurrence was 7.6, 7.9, and 9.7 months for viruria, viremia, and polyomavirus-associated nephropathy. Risk factors associated with BKV infection in univariate analyses were retransplantation, panel-reactive antibody more than 0%, cytomegalovirus D+/R-, cold ischemia time, delayed graft function, induction with antithymocyte globulins, acute rejection before month 3 (M3), tacrolimus trough levels more than 10 ng/mL, and M3 AUC0-12 hr more than 50 hr mg/L. Multivariate analyses showed that cytomegalovirus D+/R- (adjusted hazard ratio [AHR], 2.03; P=0.05), acute rejection (AHR, 5.4; P

Published
2013

16. Utilisation des anticoagulants oraux en transplantation rénale : étude rétrospective des accidents hémorragiques dans une série monocentrique

Author

C. Muller, G. Gautier-Vargas, Francoise Heibel, Sophie Caillard, Jérôme Olagne, Laura Braun-Parvez, Noëlle Cognard, Peggy Perrin, and B. Moulin

Subjects
Nephrology
Abstract

Introduction Les patients qui presentent une insuffisance renale ont un sur-risque de thrombose et d’hemorragie. Les indications d’anticoagulation orale (ACO) dans cette population sont plus frequentes que dans la population generale en raison de l’incidence accrue de fibrillation atriale et autres complications cardiovasculaires. Nous avons evalue dans une population de transplantes renaux le risque hemorragique grâce a des scores extrapoles de la population generale et revu les evenements hemorragiques survenus. Patients et methodes Nous avons identifie 146 patients (12 % de la cohorte) traites par ACO dont nous avons compile les donnees de biologie, comorbidites, et habitus necessaires au calcul des scores CHA2DS2 VASc, mOBRI, HAS-BLED et HEMORR2HAGES [1] , [2] . Les accidents hemorragiques severes (necessitant une hospitalisation ou une transfusion) ont ete releves. Les caracteristiques des patients transplantes a haut risque de saignement ont ete identifiees. Resultats Un accident hemorragique est survenu chez 45 % des patients sous ACO, 34 % concernaient le site de la transplantation en postoperatoire, 22 % etaient digestifs, et 8 % intracrâniens. Quatorze pour cent des patients avec ACO avaient un score CHA2DS2 VASc Discussion Les saignements sont un accident frequent en post-transplantation. Le score predictif HEMORR2HAGES parait le plus adapte a notre population. Un groupe particulier de patients a haut risque de saignement peut etre identifie qui beneficierait d’adaptations therapeutiques personnalisees. Conclusion Les saignements sous ACO sont une complication frequente apres transplantation renale necessitant une evaluation benefice–risque a chaque introduction de traitement.

Published
2015

17. Fistule artérioveineuse en hyperdébit après transplantation rénale, une situation fréquente aux conséquences sous-estimées : étude prospective d’une cohorte de transplantés un an après la greffe

Author

S. Talha, Laura Braun-Parvez, Francoise Heibel, Nicolas Keller, B. Moulin, A. Monnier, Noëlle Cognard, C. Muller, Sophie Caillard, G. Gautier-Vargas, and Peggy Perrin

Subjects
Nephrology
Abstract

Introduction La mortalite cardiovasculaire est la principale cause de deces chez les patients ayant eu une transplantation renale. Parmi les facteurs de risque de cardiopathie, les effets hemodynamiques de la fistule arterioveineuse (FAV) notamment en condition d’hyperdebit ont ete peu etudies. L’objectif de notre travail a ete de determiner la prevalence des FAV en hyperdebit un an apres transplantation et les modifications echocardiographiques associees. Patients et methodes Au total, 41 patients ayant eu une transplantation renale (29H et 12F, âge 57 ± 12 ans), hemodialyses sur FAV avant la transplantation ont ete etudies prospectivement entre fevrier 2014 et avril 2015 a 1 an de leur transplantation. 95 % des patients etaient traites par anticalcineurines (11 CsA ; 28 FK). La creatininemie etait de 142 ± 49 μmol/L et l’hemoglobine de 12,7 ± 1,7 g/dL. Une mesure du debit de FAV et une ETT ont ete realisees dans le meme temps. L’hyperdebit absolu etait defini par un debit dans la FAV > 2 L/min et l’hyperdebit relatif par un debit dans la FAV > 1 L/min associe a un ratio debit FAV sur debit cardiaque > 20 %. Resultats Dans notre population, le debit moyen dans la FAV etait de 1622 ± 807 mL/min, le debit cardiaque de 5,9 ± 1,1 L/min, la FEVG de 69 ± 7 % et le score NYHA de 2 ± 1. 70,7 % des patients avaient une hypertrophie ventriculaire gauche (HVG). Un hyperdebit de FAV a ete mis en evidence chez 66 % des patients (debit moyen 2016 ± 786 mL/min). Dans 32 % des cas, il s’agissait d’un hyperdebit absolu et dans 34 % d’un hyperdebit relatif. Trois patients avaient une insuffisance cardiaque a haut debit dont 2 cas secondaires a un hyperdebit de FAV. Seuls les diametres telesystoliques ( p = 0,01) et telediastoliques du ventricule gauche (DTDVG) ( p = 0,02) etaient significativement plus eleves dans le groupe hyperdebit. Discussion La prevalence particulierement elevee d’un hyperdebit de FAV a 1 an de la transplantation renale suggere l’importance du suivi hemodynamique de ces patients, de determiner les indications de la ligature de FAV et d’en evaluer les eventuels benefices en termes de regression des anomalies cardiaques par un travail ulterieur. Conclusion La ligature de la FAV pourrait permettre une diminution de la dilatation ventriculaire gauche chez les transplantes renaux comme cela vient d’etre recemment suggere [1] .

Published
2015

18. Rejet humoral aigu tardif et rejet humoral chronique : différentes entités et différentes prises en charge

Author

G. Gautier-Vargas, Peggy Perrin, C. Muller, Francoise Heibel, Noëlle Cognard, Jérôme Olagne, Laura Braun-Parvez, B. Moulin, A. Essaydi, A. Parissiadis, and Sophie Caillard

Subjects
Nephrology
Abstract

Introduction La distinction histologique entre le rejet humoral aigu tardif (RHAT) et le rejet humoral chronique (RHC) a ete revisee recemment dans la classification de Banff 2013. Le pronostic de ces deux diagnostics et surtout leur prise en charge restent a preciser. Patients et methodes Nous avons analyse les patients avec un diagnostic de rejet humoral (aigu ou chronique) survenu apres 1 an de greffe prouve par biopsie et un anticorps contre le greffon (DSA) mis en evidence par technique Luminex, entre 2008 et 2014. Nous avons releve les traitements mis en œuvre, l’evolution des valeurs de fluorescence des DSA, et le pronostic renal de ces patients avec au moins un an de recul. Resultats Un diagnostic de rejet humoral a ete pose chez 89 patients (RHAT : n = 36, RHC : n = 53). L’âge moyen etait de 51,2 ans et il y avait 55 % d’hommes. Les DSA mis en evidence etaient le plus souvent de classe II (82 %) et de novo (81 %). Les patients ayant un RHC avaient un debit de filtration glomerulaire estime (DFGe) plus bas au moment de la biopsie (35 vs 45 mL/min/1,73 m 2 , p = 0,008), ainsi qu’un an apres le diagnostic ( p = 0,001). La proteinurie etait plus elevee dans le groupe RHC (1,7 versus 0,9 g/j, p = 0,13). Cinquante et un pour cent des patients ont perdu leur greffon dans le groupe RHC vs 33 % dans le groupe RHAT ( p = 0,10) dans un delai moyen de 2,5 ans. La MFI des DSA etait plus elevee dans le groupe RHC a j0, et significativement a 3 et 6 mois apres le diagnostic de rejet ( p = 0,002 et 0,005, respectivement). Les patients avec RHC ont ete moins traites (45 vs 89 %, p p 2 au diagnostic, l’arterite inflammatoire et le delai entre la detection du DSA et le diagnostic de rejet. Discussion Le RHC est associe a un mauvais pronostic de survie du greffon et la mise en route d’un traitement n’influence pas l’evolution de la fonction renale dans notre etude. Conclusion Il est important de bien identifier les lesions histologiques caracteristiques lorsqu’un rejet humoral survient apres la 1 re annee afin de bien differencier RHAT et RHC.

Published
2015

19. Hyalinose segmentaire et focale récidivante après transplantation rénale : tentative de traitement par abatacept

Author

G. Gautier-Vargas, Sophie Caillard, Jérôme Olagne, Peggy Perrin, Francoise Heibel, Laura Braun-Parvez, C. Muller, and B. Moulin

Subjects
Nephrology
Abstract

Introduction La survenue d’un syndrome nephrotique (SN) apres transplantation renale chez les patients greffes pour hyalinose segmentaire et focale (HSF) est frequente. Cette recidive resiste souvent aux therapeutiques classiques. Dans cette situation, l’abatacept, dont l’efficacite a ete recemment rapportee [1] , est tente en derniers recours chez un patient. Patients et methodes Monsieur C, 50 ans, greffe pour HSF en 2003, presente une recidive postoperatoire, partiellement controlee a m1 par ciclosporine intraveineuse (IV) et 13 plasmaphereses (EP), puis retourne en dialyse en 2011. Une seconde transplantation est effectuee en 2012, avec plasmapherese preoperatoire, ciclosporine IV et trandolapril. Une recidive a m1 est traitee par ciclosporine IV et EP pluri-hebdomadaires. Le SN recidivera des espacement des EP, a m3 malgre l’association au rituximab, a m6 malgre la reprise de la ciclosporine IV, a m12 apres 12 seances d’immuno-adsorption. A m15, apres 3 mois supplementaires d’EP pluri-hebdomadaires, 2 perfusions d’abatacept (10 mg/kg), espacees de 15 jours, sont realisees. Resultats La tolerance est bonne mais sans efficacite sur la proteinurie qui reste elevee (> 10 g/j). Un EP hebdomadaire est maintenu au long cours. Discussion et conclusion L’abatacept inhibe la costimulation, en ciblant B7-1, dont l’expression podocytaire est activee dans divers modeles animaux de nephropathie proteinurique, et chez des patients atteints notamment de HSF. A la difference des remissions d’HSF constatees chez 5 patients (dont 4 transplantes) dans la recente serie de Boston, ce traitement reste inefficace chez notre patient, soulignant la necessite d’etudes supplementaires. La limite de notre approche concerne l’absence de recherche de l’expression de B7-1 sur les biopsies de greffon.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results